The apoptosis-inducing Fas ligand (FasL) is expressed in a variety of human cancers and has been implicated in tumor immune evasion. Paradoxically, ectopic expression of FasL in experimental tumors triggers a neutrophil-mediated inflammatory response and tumor rejection. To resolve these conflicting findings, we have established B16 melanoma and P29 Lewis lung carcinoma lines expressing different levels of FasL and examined their tumorigenicity in vivo. While tumors with a high level of FasL were rapidly rejected as previously reported, those expressing a low level of FasL were not rejected but grew faster than did FasL-negative parental cells. The growth enhancement of FasL low tumors was not observed in T-cell-deficient nude mice, suggesting that FasL expressed in tumors at low levels counteracted against T-cell-dependent antitumor responses. In support of this notion, FasL low tumors were found to grow faster than parental cells in mice that had acquired tumor-specific immunity. Furthermore, histological examinations revealed apoptosis of lymphocytes in tissue sections of FasL low tumors. These results collectively suggest that FasL on tumors is a double-edged sword: at high levels it triggers tumor rejection whereas at low levels it facilitates tumor growth possibly by suppressing antitumor immune responses.
Introduction
The Fas/Fas ligand (FasL) system plays a central role in the elimination of activated T and B cells and downregulation of immune responses. [1] [2] [3] FasL is expressed in the eye and testis where its pro-apoptotic activity, along with a variety of other immunosuppressive factors, is considered to contribute to the immune privilege status of these tissues. [3] [4] [5] [6] FasL is also expressed by many human tumors and is associated with poor prognosis in breast, 7, 8 ovarian 9 and liver 10 cancers, leading to the hypothesis that tumors use FasL to counterattack the tumorinfiltrating cytotoxic T cells and to escape the immune clearance. 11, 12 In contrast to these observations, tumor cells engineered to express exogenous FasL triggered a potent neutrophil-mediated local inflammatory response and were rapidly rejected. [13] [14] [15] [16] These conflicting findings have led to extensive debates on the role of FasL in immune privilege versus inflammation. 11, 12, 17, 18 It has been proposed that the effect of FasL may depend on its expression level 12 this hypothesis needs further evidences. In the present study, we have established B16 melanoma and P29 Lewis lung carcinoma lines expressing low, medium and high levels of FasL by using a sensitive in vitro killing assay. We demonstrated that FasL at high levels triggered an inflammatory response and subsequent tumor rejection but at low levels it enhanced tumor growth with inducing little inflammation. We also showed that a low level of FasL conferred a growth advantage to tumors in mice that had acquired tumor-specific immunity. These results demonstrated that the effects of FasL on inflammation and tumor survival were dependent on its expression levels and thereby caution against using FasL as an adjuvant in cancer immune therapy.
Materials and methods

Mice
Six-to 8-week-old female C57BL/6 (B6) and BALB/c nu/ nu (nude) mice were purchased from Japan SLC (Shizuoka, Japan) and maintained in our animal facility under specific pathogen-free conditions. Animal experiments were performed according to the guide for the care and use of laboratory animals of Chiba Cancer Center.
Cell culture B16 (a mouse melanoma cell line) and P29 (a Lewis lung carcinoma cell line), 19 which are of B6 origin, were cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal calf serum (FCS). Spleen B and T cells were cultured in Rosewell's Park Memorial Institute (RPMI)1640 medium supplemented with 10% FCS. The cells were cultured at 371C with 5% CO 2 in a humidified atmosphere.
Establishment of FasL-expressing cells
A full-length mouse FasL cDNA was cloned by reverse transcription-polymerase chain reaction (RT-PCR) from anti-CD3 antibody (Ab)-activated spleen T cells. After confirming the nucleotide sequence, the FasL cDNA was subcloned into pMKITneo to generate the expression vector pMKIT-FasL. B16 and P29 cells were transfected with pMKIT-FasL with the Lipofectin Reagent (Life Technologies, Gaithersburg, MD). G418-resistant clones were selected and examined for their surface FasL expression with killing activities against activated B lymphocytes.
Determination of the cytotoxic activity of FasL transfectants Spleen cells of B6 mice were cultured in the presence of soluble CD40 ligand (CD40L) for 2 days to induce their Fas expression and FasL susceptibility. 20 . The CD40L-activated spleen B cells were then cocultured with adherent monolayered tumor cells for 4 h and stained with fluorescein isothiocyanate-conjugated anti-B220 Ab (PharMingen, San Diego, CA) and 1 mg/ml propidium iodide (PI). The stained cells were analyzed with a FACScan cytometer using the CellQuest software (Becton Dickinson, San Jose, CA). The Jo-2 anti-Fas Ab (PharMingen) was used as a positive control for apoptosis induction of Fas-positive B cells.
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay Mice were inoculated with 10 7 tumor cells and 5 days later paraffin-embedded tissue biopsy sections were prepared. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining was carried out with an apoptosis detection kit (TaKaRa, Tokyo, Japan) according to the company's protocol. 
Animal experiments
Apoptosis induction of lymphocytes by FasL low tumors
The elevated growth of FasL low tumors in immunocompetent but not in T-cell-deficient nude mice suggests that a low level of FasL counteracts against T-cell-dependent antitumor immunity. We therefore investigated whether the low level of FasL can induce apoptosis of lymphocytes by using a TUNEL assay. A few scattered TUNELpositive cells, most likely lymphocytes as judged from their morphology, were detected in FasL low tumor sections ( Figure 5 ). The frequency of the apoptotic cells, however, was quite low, consistent with the minimal killing activity of FasL low tumors probably because the apoptotic cells were rapidly removed.
Enhanced growth of FasL low tumors in mice that have acquired antitumor immunity
The above results suggested that FasL low tumors were capable of killing tumor-infiltrating lymphocytes. We then asked whether a low level of FasL could protect tumors against established tumor-specific immunity. As we and others previously reported, mice that had once rejected the FasL high lines developed a T-cell-dependent tumor-specific immunity, which could significantly inhibit the growth of FasL-negative parental tumors subsequently inoculated. 13, 21 The growth of parental B16 cells was apparently slower in FasL high -immunized mice than that in unimmunized naive mice ( Figure 6 ). Notably, both of the FasL low tumor lines grew significantly faster than parental cells (Po0.05, Student's t-test). These results indicated that a low level of FasL on tumors conferred a growth advantage to tumors even in mice that had acquired antitumor immunity.
Discussion
A large number of human cancers have been shown to express FasL. 12. In most cases, FasL expression was examined by either RT-PCR or immunostaining and it was difficult to quantify the precise levels. 17 Many human tumor cell lines have also been shown to express various levels of FasL and kill T cells under in vitro conditions. However, these cell lines have not been tested for their tumor formation in vivo. By using a sensitive B-cell killing assay, we were able to determine the relative levels of FasL ectopically expressed in tumors and examine their growth in vivo. In two histologically distinct mouse tumor models, B16 melanoma and P29 lung carcinoma, we demonstrated that a low level of FasL induced few neutrophil-mediated inflammatory responses or tumor rejection but rather facilitated tumor growth in vivo. This is in striking contrast with a high level of FasL, which has been shown to induce complete tumor rejection.
Tumors expressing a high level of FasL were rapidly rejected and this rejection was observed in both immunocompetent and T-cell-deficient nude mice. 13, 21 The primary rejection per se therefore was attributable to neutrophil-mediated inflammation and was T-cellindependent. Nevertheless, a tumor-specific protective immunity was established in the immunocompetent mice following the rejection. 21 This implies that T cells participate in the primary antitumor immune response and are primed even though they do not play a major role in the rejection. The growth enhancement of FasL low tumors observed in immunocompetent but not nude mice is consistent with a role of T cells during the primary immune response. The enhancement was also demonstrated in the mice that developed T-cell-mediated immunity against the tumors. We also detected FasLdependent T-cell apoptosis when cocultured with FasL It is not yet fully understood how FasL induces inflammation. Earlier studies indicated that the membrane bound FasL may be released from cell surface after protease-mediated cleavage and the soluble form may act as a chemotactic factor that induces the migration of neutrophils. 3, 22 In contrast, we have found that soluble form of FasL did not trigger apparent inflammation or tumor rejection. 23 A recent study provided evidence that FasL-triggered inflammation correlated with its cytotoxic activity and was in fact a secondary effect of the locally induced apoptosis. 16 Accordingly, the induction of inflammation may depend not only on the level of FasL on tumors but also on the FasL susceptibility of the surrounding tissues. It is possible that certain human tumors may express high levels of FasL to counterattack the immune effector cells without inducing an inflammatory response if their adjacent tissues are resistant to Fasmediated apoptosis. Such tumors may resemble the two immune privileged normal tissues, the eye and the testis, which express FasL but are resistant to Fas-mediated apoptosis in the local milieu.
The results of the present study explain the opposing observations that many human cancers are FasL þ yet experimental tumors expressing a high level of FasL are rejected. Our results suggest a possible risk of FasL usage as an adjuvant in cancer immunotherapy when the lower expression was induced. Adenovirus-mediated FasL expression at a high level is a strategy to avoid the risk and the strategy may produce bystander effects through apoptotic bodies. 25 Application of FasL to cancer therapy deserves further studies to estimate the feasibility.
Abbreviations
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